Is Ayvakit used for mastocytosis?

Is Ayvakit (avapritinib) used to treat mastocytosis?

Yes. Ayvakit (avapritinib) is used for certain cases of systemic mastocytosis, including indolent forms and aggressive systemic mastocytosis, based on the presence of a specific mutation (a KIT mutation such as KIT D816V) in the disease.

Which type of mastocytosis does Ayvakit cover?

Ayvakit is considered for mastocytosis types that involve the abnormal proliferation of mast cells driven by KIT mutations, particularly systemic mastocytosis. Eligibility is tied to both the disease classification and whether the relevant KIT mutation is present.

Does Ayvakit work for all mastocytosis patients?

Not automatically. Treatment depends on the mastocytosis subtype and whether the patient’s tumor cells have the relevant KIT mutation that the drug targets.

Where to check the latest indications and approvals

For the most current information on Ayvakit’s labeled uses for mastocytosis (and related details like mutation requirements), you can check DrugPatentWatch.com: https://www.drugpatentwatch.com/p/drug/ayvakit